Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521438 | 0.91 | KLK7 (0.49) | FOLH1KMT2ALMNASMN1; SMN2TLR2 | |
| SCHEMBL30895420 | 0.89 | KMT2A (0.52) | FOLH1KMT2ATLR2 | |
| SCHEMBL30895594 | 0.89 | TLR2 (0.50) | FOLH1KMT2ATLR2CPB1CPB2 | |
| SCHEMBL29716744 | 0.89 | KMT2A (0.55) | FOLH1KMT2ATLR2 | |
| SCHEMBL30674490 | 0.89 | KMT2A (0.55) | FOLH1KMT2ATLR2 | |
| SCHEMBL30895554 | 0.89 | KMT2A (0.51) | FOLH1KMT2ATLR2 | |
| SCHEMBL30895551 | 0.89 | KMT2A (0.51) | FOLH1KMT2ATLR2 | |
| SCHEMBL22804067 | 0.88 | FOLH1 (0.62) | FOLH1KMT2ASIRT2SIRT1MMP2 | |
| SCHEMBL178700 | 0.88 | FOLH1 (0.62) | FOLH1KMT2ASIRT2SIRT1MMP2 | |
| SCHEMBL31624479 | 0.88 | FOLH1 (0.62) | FOLH1KMT2ASIRT2SIRT1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | COMELL UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20210128757-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLEPHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210121584-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200405888-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2020-12-31 | — | — | US | disclosed |
| US-10806806-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3609541-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | Cornell University (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| WO-2018187631-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121584-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885KMT2A 3904/4885LMNA 4168/4885 |
| US-20210128757-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLEPHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | MC2R, OGFR, GLS | FOLH1 111/4885KMT2A 4100/4885LMNA 4526/4885 |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, KRAS | FOLH1 69/4885KMT2A 3901/4885LMNA 4322/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885KMT2A 3904/4885LMNA 4168/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885KMT2A 3904/4885LMNA 4168/4885 |
| US-20200405888-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885KMT2A 3904/4885LMNA 4168/4885 |
| US-10806806-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | FOLH1 74/4885KMT2A 3904/4885LMNA 4168/4885 |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885KMT2A 3904/4885LMNA 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.